×
About 5,365 results

ALLMedicine™ Brain Metastasis Center

Research & Reviews  1,748 results

Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other...
https://clinicaltrials.gov/ct2/show/NCT04588246

Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine if salvage stereotactic radiosurgery (SRS) plus whole brain radiotherapy with hippocampal avoidance (HA-WBRT) in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second d...

Defibrotide suppresses brain metastasis by activating the adenosine A2A receptors.
https://doi.org/10.1097/CAD.0000000000001372
Anti-cancer Drugs; Dong C, Zhu L et. al.

Aug 11th, 2022 - Brain metastasis is a devastating clinical condition globally as one of the most common central nervous system malignancies. The current study aimed to assess the effect of defibrotide, an Food and Drug Administration-approved drug, against brain ...

A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lun...
https://doi.org/10.1097/CAD.0000000000001363
Anti-cancer Drugs; Cheng W, Qian C et. al.

Aug 11th, 2022 - Anaplastic lymphoma kinase (ALK) rearrangement defines a unique nonsmall cell lung cancer (NSCLC) molecular subtype, of which the patients could potentially benefit from anti-ALK therapies. So far, the outcomes of the canonical echinoderm microtub...

False-negative and false-positive outcomes of computer aided detection on brain metasta...
https://doi.org/10.1093/neuonc/noac192
Neuro-oncology Luo X, Yang Y et. al.

Aug 10th, 2022 - Errors have seldom been evaluated in computer-aided detection on brain metastases. This study aimed to analyze false negatives (FNs) and false positives (FPs) generated by a brain metastasis detection system (BMDS) and by readers. A deep learning-...

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
https://clinicaltrials.gov/ct2/show/NCT04674683

Aug 10th, 2022 - This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab. Randomization of eligible patients will be stratified by PD-L1 expression (positive, ≥1% expression level versus nega...

see more →

Guidelines  2 results

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patien...
https://doi.org/10.1016/j.annonc.2021.07.016
Annals of Oncology : Official Journal of the European Soc... Le Rhun E, Guckenberger M et. al.

Aug 9th, 2021 - EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.|2021|Le Rhun E,Guckenberger M,Smits M,Dummer R,Bachelot T,|diagnosis,therapy,

A Cancer Care Ontario Organizational Guideline for the Delivery of Stereotactic Radiosu...
https://doi.org/10.1016/j.prro.2019.11.002
Practical Radiation Oncology; Sahgal A, Kellett S et. al.

Nov 30th, 2019 - In Ontario, Canada, there is increasing demand for stereotactic radiosurgery (SRS) for brain metastases. Recommendations for safe SRS delivery are needed to ensure that patients receive an equitable level of care across the province. This guidelin...

see more →

Clinicaltrials.gov  234 results

Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other...
https://clinicaltrials.gov/ct2/show/NCT04588246

Aug 12th, 2022 - PRIMARY OBJECTIVE: I. To determine if salvage stereotactic radiosurgery (SRS) plus whole brain radiotherapy with hippocampal avoidance (HA-WBRT) in patients with brain metastasis velocity >= 4 new brain metastases/year at time of first or second d...

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
https://clinicaltrials.gov/ct2/show/NCT04674683

Aug 10th, 2022 - This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study of HBI-8000 or Placebo combined with nivolumab. Randomization of eligible patients will be stratified by PD-L1 expression (positive, ≥1% expression level versus nega...

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
https://clinicaltrials.gov/ct2/show/NCT03325166

Aug 10th, 2022 - PRIMARY OBJECTIVE: I. Determine the sensitivity and specificity of relative cerebral blood volume (rCBV) measured by steady state magnetic resonance imaging (MRI) with ferumoxytol in predicting true versus (vs) pseudoprogression after stereotactic...

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
https://clinicaltrials.gov/ct2/show/NCT05026983

Aug 10th, 2022 - PRIMARY OBJECTIVES: I. To evaluate antitumor activity of high dosing regimen of encorafenib + binimetinib combination therapy for patients with BRAFV600-mutant melanoma and/or leptomeningeal disease (LMD) as measured by progression free survival (...

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
https://clinicaltrials.gov/ct2/show/NCT03909334

Aug 2nd, 2022 - The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to ...

see more →

News  162 results

Multidisciplinary Teams Key to Brain Metastasis Care
https://www.medscape.com/viewarticle/977943

Jul 26th, 2022 - Multidisciplinary disease management teams (MDTs) that span inpatient and outpatient settings, as well as dedicated tumor boards, are necessary to realize the promise of advances in the treatment of brain metastasis and guide clinician decision ma...

ALK+ advanced NSCLC with brain mets: Lorlatinib boosts PFS, reduces CNS progression
https://www.mdedge.com/hematology-oncology/article/255649/lung-cancer/alk-advanced-nsclc-brain-mets-lorlatinib-boosts-pfs

Jun 22nd, 2022 - Key clinical point : Lorlatinib extends progression-free survival (PFS) and reduces central nervous system (CNS) progression compared with crizotinib in patients with anaplastic lymphoma kinase positive ( ALK+) advanced nonsmall cell lung cancer (.

ASCO 2022: An Abundance of Data for the Field of Melanoma
https://www.medscape.com/viewarticle/975371

Jun 22nd, 2022 - Michael Postow, MD, offers an immediate reflection on compelling data surrounding adjuvant and neoadjuvant treatments for melanoma, as well as other items of clinical interest, presented at the ASCO 2022 conference. An update on the KEYNOTE-716 tr...

NSCLC with brain metastasis: ICI-radiotherapy combo prolongs OS vs chemoradiotherapy
https://www.mdedge.com/hematology-oncology/article/254927/lung-cancer/nsclc-brain-metastasis-ici-radiotherapy-combo

May 24th, 2022 - Key clinical point : Immune checkpoint inhibitors (ICI) plus radiotherapy (RT) conferred an overall survival (OS) benefit over chemotherapy plus RT after resection of brain metastasis from non-small cell lung cancer (NSCLC). Major finding : The ch.

Prognostic factors in male breast cancer with bone metastases
https://www.mdedge.com/hematology-oncology/article/254754/breast-cancer/prognostic-factors-male-breast-cancer-bone

May 18th, 2022 - Key clinical point: Age, tumor subtype, surgery, and brain metastasis are independent risk factors for survival in male patients with breast cancer (BC) and bone metastases and should be considered when devising a treatment strategy. Major finding.

see more →